Mission Statement
The Cancer Diagnosis Program (CDP) strives to improve the diagnosis and assessment of cancer by effectively moving new scientific knowledge into clinical practice. The program stimulates, coordinates, and supports resources and research in the following areas:
- Development of innovative in vitro diagnostics and novel diagnostic technologies
- Procurement of appropriate human specimens for research
- Characterization of cancers to improve clinical decision making and evaluation of response to treatment
The CDP is a part of the Division of Cancer Treatment and Diagnosis (DCTD) in the National Cancer Institute, which is part of the National Institutes of Health. CDP supports research at medical centers, hospitals, businesses, and universities throughout the United States. The CDP is not directly involved with patient care. Information for cancer patients and for health care providers about cancer diagnosis can be found on the NCI Home Page.
Organization
The Cancer Diagnosis Program includes the Office of the Associate Director (OAD) and four Branches:
- Office of the Associate Director (OAD)
- Biorepositories and Biospecimen Research Branch (BBRB)
- Diagnostic Biomarkers and Technology Branch (DBTB)
- Diagnostics Evaluation Branch (DEB)
- The Pathology Investigation and Resources Branch (PIRB)